SCHEMBL5863183

SCHEMBL5863183

CCOC(=O)c1ccc(-c2ccc(CSCCOc3ccccc3)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.53
TDP1 Q9NUW8 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.49
KCNH2 Q12809 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
PTPN1 P18031 1/20 0.47
RAB9A P51151 1/20 0.46
POLB P06746 1/20 0.45
RARA P10276 1/20 0.45
RARB P10826 1/20 0.45
RARG P13631 1/20 0.45
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
DHFR P00374 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863106 0.90 TDP1 (0.52) MAPTTDP1L3MBTL1SMN1; SMN2KCNH2
SCHEMBL5863113 0.90 MEN1 (0.51) MAPTTDP1L3MBTL1SMN1; SMN2MEN1
SCHEMBL5863074 0.85 MAPT (0.50) MAPTTDP1L3MBTL1SMN1; SMN2KCNH2
SCHEMBL5863181 0.85 SMN1; SMN2 (0.47) MAPTTDP1L3MBTL1SMN1; SMN2MEN1
SCHEMBL5863142 0.85 PKM (0.58) POLBRARB
SCHEMBL5863076 0.82 MEN1 (0.52) MAPTTDP1L3MBTL1SMN1; SMN2MEN1
SCHEMBL5863054 0.81 CA2 (0.49) MAPTSMN1; SMN2MEN1KMT2APTPN1
SCHEMBL20144307 0.78 L3MBTL1 (0.53) MAPTTDP1L3MBTL1SMN1; SMN2MEN1
SCHEMBL11602353 0.77 TDP1 (0.58) MAPTTDP1L3MBTL1SMN1; SMN2KCNH2
SCHEMBL5863173 0.77 MRGPRX4 (0.53) KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132456-B2 MCH receptor antagonists ELI LILLY AND COMPANY (US) 2006-11-07 US disclosed
US-20060052449-A1 Novel mch receptor antagonists ELI LILLY AND COMPANY 2006-03-09 US disclosed
EP-1572637-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-09-14 EP disclosed
WO-2004052848-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052449-A1 Novel mch receptor antagonists MCHR1, MCHR2, MC1R MAPT 1595/4885TDP1 4438/4885L3MBTL1 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.